Johnson & Johnson (NYSE:JNJ) Shares Down 1.7% - Here's What Happened

Key Points

• Johnson & Johnson's shares fell by 1.7% during mid-day trading, with the stock last priced at $174.25.
• Analysts have set a median price target of $177.87 for Johnson & Johnson, with ratings ranging from "Strong Buy" to "Hold" among various research firms.
• The company recently declared a quarterly dividend of $1.30 per share, representing an annual yield of 3.0%.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price fell 1.7% on Thursday . The stock traded as low as $173.87 and last traded at $174.25. 8,025,844 shares were traded during mid-day trading, a decline of 9% from the average session volume of 8,860,296 shares. The stock had previously closed at $177.20.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on JNJ. UBS Group raised their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Finally, Citigroup lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $177.87.

Johnson & Johnson Price Performance

The firm has a market capitalization of $423.80 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The business has a 50-day moving average of $172.80 and a 200 day moving average of $161.64. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Institutional Trading of Johnson & Johnson

Large investors have recently modified their holdings of the business. W.H. Cornerstone Investments Inc. lifted its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company's stock valued at $1,206,000 after purchasing an additional 58 shares during the last quarter. YANKCOM Partnership boosted its stake in shares of Johnson & Johnson by 0.8% during the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company's stock valued at $1,076,000 after buying an additional 58 shares during the period. Greenup Street Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company's stock worth $309,000 after acquiring an additional 60 shares in the last quarter. Ellis Investment Partners LLC lifted its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock worth $1,307,000 after purchasing an additional 62 shares during the last quarter. Finally, Cypress Wealth Services LLC increased its position in Johnson & Johnson by 0.9% during the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company's stock worth $1,013,000 after acquiring an additional 62 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.